文献速递骨软组织肉瘤与黑色素瘤

新辅助病灶内Daromun治疗可切除局部晚期黑色素瘤:PIVOTAL III期试验疗效与安全性更新

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.
PubMed 文献 · J Clin Oncol · 2026-08-11

PIVOTAL III期试验入组256例完全可切除III期黑色素瘤患者,比较新辅助病灶内Daromun(L19IL2/L19TNF)后手术与直接手术。本次更新分析中位随访36.8个月,证实RFS和远处无转移生存获益,事件无生存事后分析一致,未发现新安全性信号。

要点

  • 更新分析中位随访36.8个月,证实RFS和远处无转移生存获益。
  • 事件无生存事后分析在总体和复发亚组中一致,未发现新安全性信号。

核心结论

  • 新辅助病灶内Daromun后手术较直接手术显著改善可切除III期黑色素瘤患者的RFS,更新分析证实获益并显示事件无生存分析一致。

研究设计与样本

  • PIVOTAL为III期试验(NCT02938299),入组256例完全可切除III期黑色素瘤患者,随机分配至Daromun后手术或直接手术。
  • 试验包含新诊断转移性疾病患者34例(13%)和术后复发患者222例(87%)。

主要发现

  • 更新分析证实RFS和远处无转移生存的临床和统计学显著改善。
  • 事件无生存事后分析在总体人群和复发亚组(无论是否接受过既往系统治疗)中一致。
  • 未记录到新的安全性信号。

关键数值与推荐

  • 更新分析中位随访36.8个月,证实RFS和远处无转移生存获益。

临床怎么用

  • 对于完全可切除III期黑色素瘤,新辅助病灶内Daromun后手术可能作为改善RFS的治疗选择。
  • 复发患者亚组(包括既往接受过系统治疗者)的事件无生存分析一致支持获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Daromun (L19IL2/L19TNF) was investigated as a neoadjuvant, intralesional therapy for patients with fully resectable stage III melanoma in the phase III PIVOTAL trial (ClinicalTrials.gov identifier: NCT02938299). The trial enrolled 256 patients in the European Union and met its primary end point, demonstrating a statistically significant improvement in recurrence-free survival (RFS; hazard ratio, 0.59; P = .005) for daromun followed by surgery versus up-front surgery, at a median follow-up (FU) of 21 months from random assignment. PIVOTAL included two clinically distinct subgroups, namely, patients with de novo diagnosed metastatic disease (n = 34; 13%) and patients with recurrence(s) after surgery with or without radiotherapy and/or adjuvant systemic therapies (n = 222; 87%). Here, we present an updated analysis of the primary and secondary end points, including safety data, at a median FU of 36.8 months from random assignment (database cutoff: November 28, 2025), alongside new sensitivity analyses of event-free survival (EFS). The updated analysis confirms the clinically and statistically meaningful improvements in RFS and distant metastasis-free survival recorded in the neoadjuvant daromun versus control arm. The EFS post hoc analysis, conducted in both the overall population and the recurrent patient subgroups (with or without prior systemic therapies), provides consistency and robustness to the benefit of neoadjuvant daromun observed for the primary efficacy end point. No new safety signals of concern were recorded.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hauschild A, Hassel JC, Ziemer M, et al. Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial. J Clin Oncol. 2026. PMID: 42579833. doi:10.1200/JCO-26-00852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。